|
|
|
|
Document Preview Collaboration and License Agreement |
||||
|
|
||||
|
Click "Add to Cart" button to purchase document. |
||||
|
|
||||
|
Title: |
Collaboration and License Agreement |
|||
|
Entities: |
Hybridon, Inc.; ISIS Pharmaceuticals, Inc.; Hale and Dorr LLP |
|||
|
Date: |
2001 |
|||
|
Size: |
Preview shows 8KB of 127KB total |
|||
|
Price: |
$57 |
|||
|
ID: |
#282253 |
|||
|
|
||||
|
||||
|
|
||||
|
Start of Preview |
||||
COLLABORATION AND LICENSE AGREEMENT
BY AND BETWEEN
ISIS PHARMACEUTICALS, INC.
AND
HYBRIDON, INC.
{Page}
TABLE OF CONTENTS
{Table}
{Caption}
PAGE
----
{S} {C}
ARTICLE I DEFINITIONS.........................................................1
SECTION 1.1 "AFFILIATE"....................................................1
SECTION 1.2 "AMINO PATENT RIGHTS"..........................................2
SECTION 1.3 "ANTISENSE PRODUCTS"...........................................2
SECTION 1.4 "ANTISENSE TECHNOLOGY"........................................2
SECTION 1.5 "CONFIDENTIAL INFORMATION".....................................2
SECTION 1.6 "DOCKET 104"...................................................2
SECTION 1.7 "DOCKET 105"...................................................3
SECTION 1.8 "DRUG POTENTIATION PATENT RIGHTS"..............................3
SECTION 1.9 "EXHIBIT K PATENTS"............................................3
SECTION 1.10 "FACILITATOR PATENT RIGHTS"...................................3
SECTION 1.11 "FINDERON PATENT RIGHTS"......................................3
SECTION 1.12 "HYBRIDON ANTISENSE DRUG".....................................4
SECTION 1.13 "HYBRIDON ANTISENSE PATENT RIGHTS"............................4
SECTION 1.14 "HYBRIDON EXCLUDED PATENT RIGHTS".............................5
SECTION 1.15 "HYBRIDON INTELLECTUAL PROPERTY"..............................5
SECTION 1.16 "IMMUNE STIMULATION PATENT RIGHTS"............................5
SECTION 1.17 "ISIS INTELLECTUAL PROPERTY RIGHTS"...........................5
SECTION 1.18 [*]
SECTION 1.19 "MOTIFS"......................................................6
SECTION 1.20 "NAKED SUBLICENSE"............................................6
SECTION 1.21 "NON-PARENT AFFILIATE"........................................6
SECTION 1.22 "OPTIMIZATION"................................................6
SECTION 1.23 "PARTY".......................................................6
SECTION 1.24 "RIBOZYMES"...................................................6
SECTION 1.25 "RIBOZYME TECHNOLOGY".........................................6
SECTION 1.26 "RNASEH DEPENDENT MECHANISMS OF ACTION".......................7
SECTION 1.27 "SUBLICENSE INCOME"...........................................7
*Confidential Treatment Requested - i -
{Page}
SECTION 1.28 "SUBLICENSEE".................................................7
SECTION 1.29 "SUBSIDIARY"..................................................7
SECTION 1.30 "THIRD PARTY LICENSE AGREEMENTS"..............................8
SECTION 1.31 "TULLIS NET SALES"............................................8
SECTION 1.32 "TULLIS PATENTS"..............................................8
SECTION 1.33 "TULLIS PRODUCT"..............................................8
SECTION 1.34 "UMASS PATENT RIGHTS".........................................8
SECTION 1.35 "VALID CLAIM".................................................8
ARTICLE II GRANT OF RIGHTS BY HYBRIDON........................................9
SECTION 2.1 LICENSE GRANT..................................................9
SECTION 2.2 SUBLICENSING RIGHT............................................11
SECTION 2.3 NO IMPLIED LICENSES; RETAINED RIGHTS..........................13
SECTION 2.4 COMMERCIALIZATION EFFORTS.....................................13
SECTION 2.5 LICENSE AGREEMENTS TO WHICH HYBRIDON IS A PARTY...............13
SECTION 2.6 METHYLGENE LICENSE AGREEMENT..................................14
SECTION 2.7 ORIGENIX LICENSE AGREEMENT....................................14
SECTION 2.8 AFFILIATES....................................................14
ARTICLE III GRANT OF RIGHTS BY ISIS..........................................14
SECTION 3.1 LICENSE GRANT.................................................14
SECTION 3.2 SUBLICENSING RIGHT............................................14
SECTION 3.3 TULLIS PATENTS................................................15
SECTION 3.4 SCOPE OF LICENSE..............................................16
SECTION 3.5 NO IMPLIED LICENSES...........................................17
SECTION 3.6 LIMITATION ON LICENSE GRANT WITH RESPECT TO TARGET
VALIDATION AND GENE FUNCTIONALIZATION ACTIVITIES.........17
SECTION 3.7 NOTICE OF HYBRIDON ANTISENSE DRUGS............................17
SECTION 3.8 AFFILIATES....................................................18
- ii -
{Page}
ARTICLE IV PAYMENT OBLIGATIONS................................................18
SECTION 4.1 CONSIDERATION FOR LICENSES OF HYBRIDON INTELLECTUAL
PROPERTY AND ISIS INTELLECTUAL PROPERTY.................18
SECTION 4.2 CONSIDERATION FOR SUBLICENSE OF TULLIS PATENTS................18
SECTION 4.3 ISIS SUBLICENSE INCOME........................................19
SECTION 4.4 RECORDS; AUDITS...............................................19
SECTION 4.5 PAYMENT CURRENCY..............................................19
SECTION 4.6 LATE PAYMENTS; COLLECTIONS....................................19
ARTICLE V COLLABORATION......................................................20
ARTICLE VI INTELLECTUAL PROPERTY PROTECTION...................................20
SECTION 6.1 PATENT PROSECUTION AND COOPERATION............................20
SECTION 6.2 ENFORCEMENT OF HYBRIDON ANTISENSE PATENT RIGHTS...............24
ARTICLE VII CONFIDENTIALITY..................................................27
SECTION 7.1 CONFIDENTIAL INFORMATION......................................27
ARTICLE VIII DISPUTE RESOLUTION..............................................28
ARTICLE IX TERM AND TERMINATION...............................................29
SECTION 9.1 TERM..........................................................29
SECTION 9.2 TERMINATION OF LICENSES AND SUBLICENSES FOR BREACH............30
SECTION 9.3 TERMINATION OF SUBLICENSE OF TULLIS PATENTS...................31
SECTION 9.4 SURVIVAL......................................................31
SECTION 9.5 SUBLICENSE SURVIVAL...........................................31
SECTION 9.6 FAILURE TO MAKE MASTER AGREEMENT DELIVERIES...................32
ARTICLE X MISCELLANEOUS PROVISIONS............................................32
SECTION 10.1 INDEMNIFICATION..............................................32
SECTION 10.2 GOVERNING LAW................................................33
SECTION 10.3 ASSIGNMENT...................................................33
|
End of Preview |
Home Intelligence Services Subscriptions News About Us